V Shakhnovich1,2,3, S Abdel-Rahman1,2, C A Friesen1,3, J Weigel1, R E Pearce1, A Gaedigk1, J S Leeder1,2, G L Kearns4. 1. Department of Pediatrics, University of Missouri Kansas City School of Medicine, Kansas City, MO, USA. 2. Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, The Childrens Mercy Hospital, Kansas City, MO, USA. 3. Division of Gastroenterology, Hepatology and Nutrition, The Childrens Mercy Hospital, Kansas City, MO, USA. 4. Section of Clinical Pharmacology and Toxicology, Arkansas Childrens Hospital, Little Rock, AR, USA.
Abstract
BACKGROUND: Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing. OBJECTIVE: To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity. METHODS: Methods: Sixty-two children (6-17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg-1 LBW). Plasma pantoprazole concentrations were measured at 10 time points over 8 h and pharmacokinetic (PK) profiles generated using non-compartmental techniques, in order to compare PK parameters of interest between children with and without obesity, while accounting for CYP2C19 genotype. RESULTS: Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs. without obesity (p=0.03). LBW-based dosing compensated for this reduction in CL/F (p = 0.15). CONCLUSION: To achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole.
BACKGROUND:Children with obesity are more likely to suffer gastroesophageal reflux disease, requiring acid-suppression therapy with proton pump inhibitors (PPIs) and no guidelines regarding dosing. OBJECTIVE: To prospectively evaluate lean-body-weight-based (LBW) dosing of the PPI pantoprazole for children with and without obesity. METHODS: Methods: Sixty-two children (6-17 years) received a one-time oral dose of liquid pantoprazole (1.2 mg kg-1 LBW). Plasma pantoprazole concentrations were measured at 10 time points over 8 h and pharmacokinetic (PK) profiles generated using non-compartmental techniques, in order to compare PK parameters of interest between children with and without obesity, while accounting for CYP2C19 genotype. RESULTS: Adjusted for milligram-per-kilogram total body weight (TBW) pantoprazole received, apparent drug clearance (CL/F) was reduced 50% in children with vs. without obesity (p=0.03). LBW-based dosing compensated for this reduction in CL/F (p = 0.15). CONCLUSION: To achieve comparable systemic PPI exposures for children with and without obesity, we recommend using LBW, rather than TBW-based dosing for pantoprazole.
Authors: Sarayut Janmahasatian; Stephen B Duffull; Susan Ash; Leigh C Ward; Nuala M Byrne; Bruce Green Journal: Clin Pharmacokinet Date: 2005 Impact factor: 6.447
Authors: Corinna Koebnick; Darios Getahun; Ning Smith; Amy H Porter; Jack K Der-Sarkissian; Steven J Jacobsen Journal: Int J Pediatr Obes Date: 2010-07-09
Authors: E Dubcenco; P M Beers-Block; L P Kim; P Schotland; J G Levine; C A McCloskey; E D Bashaw Journal: Clin Transl Sci Date: 2017-06-15 Impact factor: 4.689
Authors: Valentina Shakhnovich; P Brian Smith; Jeffrey T Guptill; Laura P James; David N Collier; Huali Wu; Chad E Livingston; Jian Zhao; Gregory L Kearns Journal: J Pediatr Date: 2018-02 Impact factor: 6.314
Authors: Kathryn E Kyler; Jonathan Wagner; Chelsea Hosey-Cojocari; Kevin Watt; Valentina Shakhnovich Journal: Paediatr Drugs Date: 2019-10 Impact factor: 3.022
Authors: Keith Feldman; Gregory L Kearns; Robin E Pearce; Susan M Abdel-Rahman; James Steven Leeder; Alec Friesen; Vincent S Staggs; Andrea Gaedigk; Jaylene Weigel; Valentina Shakhnovich Journal: Clin Transl Sci Date: 2022-02-14 Impact factor: 4.438